Genomic instability in squamous cell carcinoma of the head and neck

Anticancer Research

Volumn 16, Issue 4 C, 1996, Pages 2421-2431

  Field, J K ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Cytogenetics; Genomic instability; Head and neck squamous cell carcinoma; HPV; Oncogenes; p53; Tumour suppressor genes

Indexed keywords

ALLELE; ARTICLE; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME 18Q; CHROMOSOME 1P; CHROMOSOME 3P; CHROMOSOME 8P; CHROMOSOME 9P; DNA REPAIR; GENE LOSS; GENOME; HEAD AND NECK CARCINOMA; HETEROZYGOSITY; HUMAN; LYMPH NODE METASTASIS; ONCOGENE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; WART VIRUS;

ALLELES; CARCINOMA, SQUAMOUS CELL; GENES, TUMOR SUPPRESSOR; HEAD AND NECK NEOPLASMS; HUMANS; MICROSATELLITE REPEATS; ONCOGENES;

EID: 0029815552     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (122)

1. Cowan JM: Cytogenetics in head and neck cancer. Mol Biol Genet 25: 1073-1087, 1992.
2. Sreekantaiah Ct, Rao P, Xu L, Sacks PG, Schantz SP, Chaganti RSK: Consistent chromosomal losses in head and neck squamous cell carcinoma cell lines. Genes, Chromosomes, Cancer 11: 29-39, 1994.
3. Jin Y, Mertens F, Mandahl N, Heim S, Olegard C, Wennerberg J, Biorklund A, Mitelman F: Chromosome abnormalities In eighty-three head and neck squamous cell carcinomas: influence of culture conditions on karyotypic pattern. Cancer Res 53(9): 2140-2146, 1993.
4. Jin Y, Mertens F, Jin C, Akervall J, Wennerberg J, Gorunova L, Mandahl N, Heim S, Mitelman F: Nonrandom chromosome abnormalities in short-terrn cultured primary squamous cell carcinomas ofthe head and neck. Cancer Res 55(14): 3204-3210, 1995.
5. Owens W, Field JK, Howard T, Stell PM: Multiple cytogenetic aberrations in squamous cell carcinoma of the head and neck. Eur J Cancer Oral Oncol 28B: 17-22, 1992.
6. Van-Dyke DL, Worsham MJ, Benninger MS, Krause CJ, Baker SR, Wolf GT, Drumheller T, Tilley BC, Carey TE: Recurrent cytogenetic abnormalities in squamous cell carcinomas of the head and neck region. Genes Chromosom Cancer 9(3): 192-206, 1994.
7. Field JK: Oncogenes and tumour-suppressor genes in squamous cell carcinoma of the head and neck. Eur J Cancer Oral Oncol 28B: 67-76, 1992.
8. Field JK: The role of oncogenes and tumour-suppressor genes in the aetiology of oral, head and neck squamous cell carcinoma. J R Soc Med 88(1): 35P-9P, 1995.
9. Berenson JR, Yang J, Mickel R: Frequent amplification of the bcl-1 locus in head and neck squamous cell carcinomas. Oncogene 4: 1111-1116, 1989.
10. Somers KD, Cartwright SL, Schechter GL: Amplification of the int-2 gene in human head and neck squamous cell carcinomas. Oncogene 5: 915-920, 1990.
11. Leonard JH, Kearsley JH, Chenevix-Trench G, Hayward NK: Analysis of gene amplification in head-and-neck squamous cell carcinomas. Int J Cancer 48: 511-515, 1991.
12. Hunter T, Pines J: Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 79(4): 573-582, 1994.
13. Callender T, el-Naggar AK, Lee MS, Frankenthaler R, Luna MA, Batsakis JG: PRAD-1 (CCND1)/cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma. Cancer 74(1): 152-158, 1994.
14. Jares P, Fernandez PL, Campo E, Nadal A, Bosch F, Aiza G, Nayach I, Traserra J, Cardesa A: PRAD-1/cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas. Cancer Res 54: 4813-4817, 1994.
15. Michalides R, van Veelen N, Hart A, Loftus B, Wientjens E, Balm A: Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas ofthe head and neck. Cancer Res 55: 975-978, 1995.
16. Boguski MS, McCormick F: Proteins regulating Ras and its relatives. Nature 366: 643-654, 1993.
17. Barbacid M: ras genes. Ann Rev Biochem 56: 779-827, 1987.
18. Spandidos DA, Wilkie NM: Malignant transformation of early passage rodent cells by a single mutated human oncogene. Nature 310: 469-475, 1984.
19. Field JK, Spandidos DA: The role of ras and myc oncogenes in human solid tumours and their relevance in diagnosis and prognosis. A review. Anticancer Res 10: 1-22, 1990.
20. Shiraishi M, Morinaga S, Noguchi M, Shimosato Y, Sekiya T. Loss of genes on the short arm of chromosome 11 in human lung carcinomas. Jpn J Cancer Res 78: 1302-1308, 1987.
21. Vachtenheim J, Horakova I, Novotna H: Hypomethylation of CCGG sites in the 3′region of H-ras protooncogene is frequent and is associated with H-ras allele loss in non-small cell lung cancer. Cancer Res 54: 1145-1148, 1994.
22. Garcia I, Dietrich P-Y, Aapro M, Vauthier G, Vadas L, Engel E: Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras-1 protooncogenes and clinical associations in human breast carcinomas. Cancer Res 49: 6675-6679, 1989.
23. Sheng Z. M, Barrois M, Klijanienko J, Micheau C, Richard J. M, Riou G. Analysis of the c-Ha-ras-1 gene for deletion, mutation, amplification and expression in lymph node metastases of human head and neck carcinomas. Br J Cancer 62: 398-404, 1990.
24. Howell RE, Wong FS, Fenwick RG: Loss of Harvey ras heterozygosity in oral squamous carcinoma. J Oral Pathol 18: 79-83, 1989.
25. Kiaris H, Spandidos DA, Jones AS, Field JK: Loss of heterozygosity and microsatellite instability of the H-ras gene in cancer of the head and neck. Int J Oncol 5: 579-582, 1994.
26. Spandidos DA, Frame M, Wilkie NM: Expression of the normal H-ras1 gene can suppress the transformed and tumorigenic phenotypes induced by mutant ras genes. Anticancer Res 10: 1543-1554, 1990.
27. Saranath D, Chang SE, Bhoite LT, Panchal RG, Kerr IB, Mehta AR, Johnson NW, Deo MG: High frequency mutation in codons 12 and 61 of H-ras oncogene in chewing tobacco-related human oral carcinoma in India. Br J Cancer 63: 573-578, 1991.
28. Spandidos DA, Lamothe A, Field JK: Multiple transcriptional activation of cellular oncogenes in human head and neck solid tumours. Anticancer Res 5: 221-224, 1985.
29. Field JK, Lamothe A, Spandidos DA: Clinical relevance of oncogene expression in head and neck tumours. Anticancer Res 6: 595-600, 1986.
30. Field JK, Yiagnisis M, Spandidos DA, Gosney JR, Papadimitriou K, Vaughan ED, Stell PM: Low levels of ras p21 oncogene expression correlates with clinical outcome in head and neck squamous cell carcinoma. Eur J Surg Oncol 18: 168-176, 1992.
31. Azuma M, Furumoto N, Kawamata H, Yoshida H, Yanagawa T, Yura Y, Hayashi Y, Takegawa Y, Sato M: The relation of ras oncogene product p21 expression to clinicopathological status criteria and clinical outcome in squamous cell head and neck cancer. CancerJ 1: 375-380, 1987.
32. Tsuji T, Sasaki K, Hiraoka F, Shinozaki F: The immunohistochemical detection of ras p21 and its correlation with differentiation in oral cancers. J Tumour Marker Oncol 4: 415-419, 1989.
33. Scambia G, Catozzi L, Benedetti Panici P, Ferrandina G, Almadori G, Paludetti G, Cadoni G, Distefano M, Piffanelli A, Mancuso S, Maurizi M: Expression of ras oncogene p21 protein in normal and neoplastic laryngeal tissues: correlation with histopathological features and epidermal growth factor receptors. Br J Cancer 69: 959-999, 1994.
34. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK: Head and neck cancer. New Engl J Med 328: 184-194, 1993.
35. Kuo MY, Jeng JH, Chiang CP, Hahn LJ: Mutations of Ki-ras oncogene codon 12 in betel quid chewing-related human oral squamous cell carcinoma in Taiwan. J Oral Pathol Med 23(2): 70-74, 1994.
36. Kiaris H, Spandidos DA, Jones AS, Vaughan ED, Field JK: Mutations, expression and genomic instability of the H-ras protooncogene in squamous cell carcinomas of the head and neck. Br J Cancer 72: 123-128, 1995.
37. Spandidos DA, Holmes L: Transcriptional enhancer activity in the variable tandem repeat DNA sequence downstream of the human Ha-ras-1 gene. FEBS letter 218: 41-46, 1987.
38. Krontiris TG, Devlin B, Karp DD, Robert NJ, Risch N: An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. New Engl J Med 329: 517-523, 1993.
39. Adamson R, Jones AS, Field JK: Loss of heterozygosity studies on chromosome 17 in head and neck cancer using microsatellite markers. Oncogene 9: 2077-2082, 1994.
40. Nawroz H, Vanderriet P, Hruban RH, Koch W, Ruppert JM, Sidransky D: Allelotype of head and neck squamous cell carcinoma. Cancer Res 54(5): 1152-1155, 1994.
41. Scholnick SB, Sun PC, Shaw ME, Haughey BH, El-Mofty SK: Frequent loss of heterozygosity for Rb, TP53 and chromosome arm 3p, but not NMEI in squamous cell carcinomas ofthe supraglottic larynx. Cancer 73: 2472-2479, 1994.
42. Scholes AGM, Field JK: Genomic instability in head and neck cancer. In: Seifert G, Editor, Current topics in pathology, Oral pathology - actual diagnostic and prognostic aspects. Heidelberg: Springer-Verlag, 1996.
43. Field JK, Pavelic ZP, Spandidos DA, Stambrook PJ, Jones AS, Gluckman JL: The role of the p53 tumour suppressor gene in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 119: 1118-1122, 1993.
44. Field JK, Spandidos DA, Malliri A, Yiagnisis M, Gosney JR, Stell PM: Elevated p53 expression correlates with a history of heavy smoking in squamous cell carcinoma ofthe head and neck. Br J Cancer 64: 573-577, 1991.
45. Field JK, Zoumpourlis V, Spandidos DA, Jones AS: p53 expression and mutations in squamous cell carcinoma of the head and neck: Expression correlates with the patients use of tobacco and alcohol. Cancer Detect Prev 18: 197-208, 1994.
46. Brennan JA, Boyle JO, Koch WM, Goodman SN, Hruban RH, Eby YJ, Couch MJ, Forastiere AA, Sidransky D: Association between cigarette smoking and mutation of the p53 gene in squamous cell carcinoma of the head and neck. New Engl J Med 332: 712-717, 1995.
47. Liloglou T, Neville EM, Stewart MP, Donnely RJ, Spandidos DA, Field JK: Prevalence of CG-TA transitions in p53 lung carcinomas from smokers: are CpC sites alternative targets for spontaneous or induced mutagenesis. submitted 1995.
48. Field JK, Spandidos DA, Stell PM: Overexpression of the p53 gene in head and neck cancer, linked with heavy smoking and drinking. Lancet 339: 502-503, 1992.
49. Somers KD, Merrick MA, Lopez ME, Incognito LS, Schechter GL, Casey G: Frequent p53 mutations in head and neck cancer. Cancer Res 52: 5997-6000, 1992.
50. Boyle JO, Hakim J, Koch W, van der Reit P, Hruban RH, Rao RA, Correo R, Rby YJ, Ruppert JM, Sidransky D: The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 53: 4477-4480, 1993.
51. Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994.
52. Werness BA, Arnold JL, Howley PM: Association of human Papillomavirus types 16 and 18 E6 proteins with p53. Science 248: 76-79, 1990.
53. Scheffner M, Werness BA, Huibregtse JM, Levine. AJ, Howley PM: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the deregulation of p53. Cell 63: 1129-1136, 1990.
54. Hubbert NL, Sedman SA, Schiller JT: Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes. J Virol 66: 6237-6241, 1992.
55. Kessis TD, Slebos RJ, Nelson WG, Kastan MB, Plunkett BS, Han SM, Lorincz AT, Hedrick L, Cho KR: Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci USA 90: 3988-3992, 1993.
56. Munger K, Werness BA, Dyson N, Phelp WC, Harlow E, Howley PM: Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumour suppressor gene product. EMBO J 8: 4099-4105, 1989.
57. Snijders PJF, van den Brule AJC, Meijer CJLM, Walboomers JMM: Papillomaviruses and cancer of the upper digestive and respiratory tracts. Curr Topics Microbiol Immunol 186: 177-198, 1994.
58. Snijders PJF, Cromme FV, van den Brule AJC, Schrijnemakers HJF, Snow GB, Walboomers JMM: Prevalence and expression of human papillomavirus in tonsillar carcinomas indicates a possible viral etiology. J Gen Virol 73: 2059-2066, 1992.
59. Snijders PJF, Scholes AGM, Hart CA, Jones AS, Vaughan ED, Woolgar JA, Meijer CJLM, Walboomers JMM, Field JK: prevalence of mucosotropic human papillomaviruses in squamous cell carcinomas of the head and neck. Int J Cancer (in press) 1996.
60. Rees M, Leigh SEA, Delhanty JDA, Jass JR: Chromosome 5 allele loss in familial and sporadic colorectal adenomas. Br J Cancer 59: 361-365, 1989.
61. Lasko D, Cavenee W, Nordenskjold M: Loss of constitutional heterozygosity in human cancer. Ann Rev Genet 25: 281-314, 1991.
62. Latif F, Fivash M, Glenn G, Tory K, Orcutt ML, Hampsch K, Delisio J, Lerman M, Cowan J, Beckett M, Weichselbaum R: Chromosome 3p deletions in head and neck carcinomas: statistical ascertainment of allelic loss Cancer Res 52: 1451-1456, 1992.
63. Cunningham C, Dunlop MG, Wyllie AH, Bird CC: Deletion mapping in colorectal cancer of a putative tumour suppressor gene in 8p22-p21.3. Oncogene 8(5): 1391-1396, 1993.
64. Field JK, Spandidos DA, Stell PM, Vaughan ED, Evan GI, Moore JP: Elevated expression of the c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma. Oncogene 4: 1463-1468, 1989.
65. Maestro R, Gasparotto D, Vukosavljevic T, Barzan L, Sulfaro S, Boiocchi M: Three discreet regions of deletion at 3p in head and neck cancers. Cancer Res 53: 5775-5779, 1993.
66. Ah-See KW, Cooke TG, Pickford IR, Soutar D, Balmain A: An allelotype of squamous carcinoma of the head and neck using microsatellite markers. Cancer Res 54(7): 1617-1621, 1994.
67. Field JK, Tsiriyotis C, Howard P, Jones AS: Allele loss on chromosome 3 in squamous cell carcinoma of the head and neck correlates with poor clinical prognostic indicators. Int J Oncol 4: 543-549, 1994.
68. Kiaris H, Jones AS, Spandidos DA, Vaughan ED, Field JK: Loss of heterozygosity on chromosome 8 in squamous cell carcinoma of the head and neck. Int J Oncol 5: 579-582, 1994.
69. Li XH, Lee NK, Ye YW. Waber PG, Schweitzer C, Cheng QC, Nisen PD: Allelic loss at chromosomes 3p, 8p, 13q, and 17p associated with poor prognosis in head and neck cancer. J Natl Cancer Inst 86(20): 1524-1529, 1994.
70. Loughran O, Edington KG, Berry LJ, Clarke LJ, Parkinson EK: Loss of heterozygosity of chromosome 9p21 is associated with the immortal phenotype of neoplastic human head and neck keratinocytes. Cancer Res 54: 5045-5049, 1994.
71. van der Reit P, Nawroz H, Hruban RH, Corio R, Tokino K, Koch W, Sidransky D: Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. CancerRes 54: 1156-1158, 1994.
72. Lydiatt WM, Davidson BJ, Shah J, Schantz SP, Chaganti RSK. The relationship of loss of heterozygosity to tobacco exposure and early recurrence in head and neck squamous-cell carcinoma. Am J Surg 168(5): 437-440, 1994.
73. Field JK, Spandidos DA: Oncogenes and tumour suppressor genes as prognostic indicators in the development of human tumours. In: Pusztai L, Lewis CE, Yap E. editors. Regulation and Proliferation of neoplastic cells. v. 1. Oxford: Oxford UniversityPress, 59-78, 1995.
74. Field JK, Kiaris H, Risk JM, Tsiriyotis C, Adamson R, Zoumpourlis V, Rowley H, Taylor K, Whittaker J, Howard P, Beirnie JC, Gosney JR, Woolgar J, Vaughan ED, Spandidsos DA, Jones AS: Allelotype of squamous cell carcinoma of the head and neck: fractional allele loss correlates with survival. Br J Cancer 72: 1180-1188, 1995.
75. Rowley H, Jones AS, Field JK: Chromosome 18: a possible site for a tumour suppressor gene deletion in squamous cell carcinoma of the head and neck. Clin Otol 20: 266-271, 1995.
76. El-Naggar AK, Hurr K, Batsakis JG, Luna MA, Goepfert H, Huff V. Sequential loss of heterozygosity at microsatellite motifs in preinvasive and invasive head and neck squamous carcinoma. Cancer Res 55(12): 2656-2659, 1995.
77. Mead LJ, Gillespie MT, Irving LB, Campbell LJ. Homozygous and hemizygous deletions of 9p centromeric to the interferon genes in lung cancer. Cancer Res 54: 2307-2309, 1994.
78. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-756, 1994.
79. Neville EM, Stewart MP, Myskow M, Donnelly RJ, Field JK: Loss of heterozygosity at 9p23 defines a novel locus in non-small cell lung cancer. Oncogene 11: 581-585, 1995.
80. Merlo A. Gabrielson E, Mabry M, Vollmer R, Baylin SB, Sidransky D: Homozygous deletion on chromosome 9p and loss of heterozygosity on 9q, 6p, and 6q in primary human small cell lung cancer. Cancer Res 54(9): 2322-2326, 1994.
81. Washimi O, Nagatake M, Osada H, Ueda R, Koshikawa T, Seki T, Takahashi T, Takahashi T: In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cnacers. Cancer Res 55: 514-517, 1995.
82. Xiao S, Li D, Corson JM, Vijg J, Fletcher JA. Codeletion of p15 and p16 genes in primary non-small cell lung carcinoma. Cancer Res 55: 2968-2971, 1995.
83. Cairns P: Rates of p16 (MTS1) mutations in primary tumours with 9p loss. Science 265: 415-416, 1994.
84. Zhang SY, Klein-Szanto AJ, Sauter ER, Shafarenko M, Mitsunaga S, Nobori T, Carson DA, Ridge JA, Goodrow TL: Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 54(19): 5050-5053, 1994.
85. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D: 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS 1 in human cancers. Nature Medicine 1: 686-692, 1995.
86. Gailani MR, Bale SJ, Leffell DJ, DiGiovanna JJ, Peck GL, Poliak S, Drum MA, Pastakia B, McBride OW, Kase R, Greene M, Mulvihill JJ, Bale AE: Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. Cell 69: 111-117, 1992.
87. Goudie DR, Yuille MAR, Leversha MA, Furlong RA, Carter NP, Lush MJ, Affara NA, Ferguson-Smith MA: Multiple self-healing squamous epitheliomata (ESS1) mapped to chromosome 9p22-q31 in families with common ancestry. Nature Genet 3: 165-169, 1993.
88. Hibi K, Takahashi T, Yamakawa K, Ueda R, Sekido Y, Ariyoshi Y, Suyama M, Takagi H, Nakamura Y, Takahashi T: Three distinct regions involved in human lung cancer. Oncogene 7: 445-449, 1992.
89. Killary AM, Wolf ME, Giambernardi TA, Naylor SL: Definition of a tumour suppressor locus within human chromosome 3p21-p22. Proc Natl Acad Sci USA 89: 10877-10881, 1992.
90. Wu CL, Sloan P, Read AP, Harris R, Thakker N: Deletion mapping on the short arm of chromosome 3 in squamous cell carcinoma of the oral cavity. Cancer Res 54(24): 6484-6488, 1994.
91. Sundaresan V, Ganly P, Hasleton P, Rudd R, Sinha G, Bleehen NM, Rabbitts P: p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus. Oncogene 7: 1989-1997, 1992.
92. Hung J, Kishimoto Y, Sugio K, Virmani A, Mc-Intire DD, Minnna JD, Gazdar AF: Allele-specific chromosome 3p deletions occur at an early-stage in the pathogenesis of lung carcinoma. JAMA 273: 558-563, 1995.
93. Kishimoto Y, Sugio K, Mitsudomi T, Oyama T, Virmani AK, McIntire DD, Gazdar AF: Frequent loss of the short arm of chromosome 9 in resected non-smallcell lung cancers from Japanese patients and its association with squamous cell carcinoma. J CancerRes Clin Oncol 121(5): 291-296, 1995.
94. Thiberville L, Payne P, Vielkinds J, LeRiche. J, Horsman D, Nouvet G, Palcic B, Lam S: Evidence of cumulative gene losses with progression of premalignant epithelial lesions to carcinoma ofthe bronchus. Cancer Res 55: 5133-5139, 1995.
95. Field JK, Neville EM, Stewart MP, Swift A, Liloglou T, Risk JM, Ross H, Gosney JR, Donnelly RJ: Fractional allele loss data indicates distinct genetic populations in the development of non-small cell lung cancer. Proc Amer Assoc Cancer Res 37: 549, 1996.
96. Taylor K, Field JK: Allelic imbalance on chromosome 1 in squamous cell carcinoma of the head and neck. (submitted).
97. Fujiwara Y, Emi M, Ohata H, Kato Y, Nakajima T, Mori T, Nakamura Y: Evidence for the presence of two tumor suppressor genes on chromosome 8p for colorectal carcinoma. Cancer Res 53: 1172-1174, 1993.
98. Schneider SS, Schick C, Fish KE, Miller E, Pena C, Treter SD, Hui SM, Silverman GA: A serine protenase inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen gene. Proc Natl Acad Sci USA 92: 3147-3151, 1995.
99. Yoo GH, Xu HJ, Brennan JA, Westra W, Hruban RH, Koch W, Benedict WF, Sidransky D: Infrequent inactivation of the retinoblastoma gene despite frequent loss of chromosome 13q in head and neck squamous cell carcinoma. Cancer Res 54: 4603-4606, 1994.
100. Kinzler K, Nilber MC, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hamilton SR, Hedge P, Markham A, Carlson N, Joslyn G, Groden J, White R, Miki Y, Miyoshi Y, Nishisho I, Nakamura Y: Identification of a gene located at chromosome 5q that is mutated in colon cancer. Science 251: 1366-1370, 1991.
101. Uzawa K, Yoshida H, Susuki H, Tanzawa H, Shimazaki J, Seino S, Sato K: Abnormalities of the adenomatous polyposis coli gene in human oral squamous cell carcinoma. Int J Cancer 58: 814-817, 1994.
102. Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y, White R: Allelotype of colorectal carcinomas. Science 244: 207-211, 1989.
103. Sato T, Tanigami A, Yamakawa K, Akiyama F, Kasumi F, Sakamoto G, Nakamura Y: Allelotype of breast cancer: cumulative allele losses promote tumour progression in primary breast cancer. Cancer Res 50: 7184-7189, 1990.
104. Morita R, Ishikawa J, Tsutsumi M, Hikiji K, Tsukada Y, Kamidono S, Maeda S, Nakamura Y: Allelotype of renal cell carcinoma. Cancer Res 51: 820-823, 1991.
105. Tsuchiya E, Nakamura Y, Weng S, Nakagawa K, Tsuchiya S, Sugano H, Kitagawa T: Allelotype of non-small cell lund carcinoma -comparison between loss of heterzygosity in squamous cell carcinoma and adenocarcinoma. Cancer Res 52: 2478-2481, 1992.
106. Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME, Law MG: Allelotype of human bladder cancer. Cancer Res 54(2): 531-538, 1994.
107. Lynch HT, Smyrk TC, Watson P, Lanspa SJ, Lynch JF, Lynch PM, Cavalieri RJ, Boland CR: Genetics, natural history, tumour spectrum and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterol 104: 1535-1549, 1993.
108. Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP, Jarvinen H, Powell SM, Jen J, Hamilton SR, Petersen GM, Kinzler KW, Vogelstein B, de la Chapelle A: Clues to the pathogenesis of familial colorectal cancer. Science 260: 812-816, 1993.
109. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M: Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363: 558-661, 1993.
110. Fishel R, Lescoe MK, Rao MRS, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R: The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75: 1027-1038, 1993.
111. Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R, Peltomaki P, Sistonen P, Aaltonen LA, Nystrom-Lahti M, et al: Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75(6): 1215-1225, 1993.
112. Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, Kane M, Earabino C, Lipford J, Lindblom A, TannergDrd P, Bollag RJ, Godwin AR, Ward DC, Nordenskjold M, Fishel R, Kolodner R, Liskay RM: Mutation in the DNA mismatch repair gene homlogue hMLHI is associated with hereditary nonpolyposis colon cancer. Nature 368: 258-261, 1994.
113. Nicolaides NC, Papadopoulos N, Liu B, Wei Y, Carter KC, Ruben SM, Rosen C A, Haseltine WA, Fleischmann RD, Fraser CM, Adams M D, Venter JC, Dunlop MG, Hamilton SR, Peterson GM, de la Chappelle A, Vogelstein B, Kinzler KW: Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 371: 75-80, 1994.
114. Papadopoulos N, Nicolaides NC, Wei YF, Ruhen SM, Carter KC, Rosen CA, Haseltine WA, Fleischmann RD, Fraser CM, Adams MD, Venter JC, Hamilton SR, Petersen GM, Watson P, Lynch HT, Peltomaki P, Mecklin JP, de la Chapelle A, Kinzler KW, Vogelstein B: Mutation of a mutL homolog in hereditary colon cancer. Science 263: 1625-1629, 1994.
115. Han HJ, Yanagisawa A, Kato Y, Park JG, Nakamura Y: Genetic instability in pancreatic cancer and poorly differentiated type of gastric cancer. Cancer Res 53: 5087-5089, 1993.
116. Risinger JI, Berchuck A, Kohler MF, Watson P, Lynch HT, Boyd J: Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 53(21): 5100-5103, 1993.
117. Thibodeau SN, Bren G, Schaid D: Microsatellite instability in cancer of the proximal colon. Science 260: 816-819, 1993.
118. Rhyu MG, Park WS, Meltzer SJ: Microsatellite instability occurs frequently in human gastric carcinoma. Oncogene 9(1): 29-32, 1994.
119. Merlo A, Mabry M, Gabrielson E, Vollmer R, Baylin SB, Sidransky D: Frequent microsatellite instability in primary small cell lung cancer. Cancer Res 54: 2098-2101, 1994.
120. Shridhar V, Siegfried J, Hunt J, Alonso MM, Smith DI: Genetic instability of microsatellite sequences in many non-small cell lung carcinomas. Cancer Res 54: 2084-2087, 1994.
121. Field JK, Kiaris H, Howard P, Vaughan ED, Spandidos DA, Jones AS: Microsatellite instability in squamous cell carcinoma of the head and neck. Br J Cancer 71: 1065-1069, 1995.
122. Mao L, Lee DJ, Tockman MS, Erozan YS, Askin F, Sidransky D: Microsateilite alterations as clonal markers for the detection of human cancer. Proc Natl Acad Sci USA 91(21): 9871-9875, 1994.